VR Logo

Galectin Therapeutics Inc. (GALT) download report


Healthcare | Biotechnology & Pharma Research

Galectin Therapeutics Inc. (GALT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.

IPO Date: 09-Sep-2002

Pres, CEO & Director: Mr. Joel Lewis

CFO, Treasurer & Sec.: Mr. Jack W. Callicutt CPA, CPA

Listing: NASDAQ: GALT

Country: United States

Headquarters: Norcross, GA

Website: https://galectintherapeutics.com

Key Facts

Market cap: $77.80 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-34.28 Mln

Cash: $31.61 Mln

Total Debt: $29.29 Mln

Insider's Holding: 38.79%

Liquidity: Low

52 Week range: $1.19 - 4.40

Shares outstanding: 59,388,500

10 Years Aggregate:

  • CFO: $-142.63 Mln
  • EBITDA: $-145.55 Mln
  • Net Profit: $-176.44 Mln

Stock Performance

Time Period Galectin Therapeutics (GALT) S&P BSE Sensex S&P Small-Cap 600
YTD-36.71-9.18-18.78
1 month-0.76-4.78-8.00
3 months-18.63-9.66-13.65
1 Year-59.060.81-17.19
3 Years-31.9110.336.10
5 Years-11.8411.345.87
10 Years-4.3811.749.84
As on 01-Jul-2022
Year Galectin Therapeutics (GALT) S&P Small-Cap 600 S&P BSE Sensex
2021-7.5925.2721.99
2020-21.689.5715.75
2019-16.6220.8614.38
20182.68-9.705.87
2017240.8911.7327.91
2016-40.2624.741.95
2015-52.74-3.36-5.03